Julia Stieglmaier
- Hematology top 2%
- Chronic Myeloid Leukemia Treatments 4
- Oncology top 5%
- CAR-T cell therapy research 17
- Cancer Immunotherapy and Biomarkers 6
-
- Lymphoma Diagnosis and Treatment 5
-
- Acute Lymphoblastic Leukemia research 5
- Immunology top 10%
- Immunotherapy and Immune Responses 5
-
- Monoclonal and Polyclonal Antibodies Research 8
-
- Prostate Cancer Treatment and Research 5
- Co-authors
- Dirk NagorsenRalf C. BargouJonathan BenjaminNicola GökbugetHervé DombretMonika BrüggemannGerhard ZugmaierCarlos Graux
- Partner nations
- GermanyUnited StatesJapan
In The Last Decade
Julia Stieglmaier
24 papers receiving 1.4k citations
Hit Papers
Peers
Comparison fields: 5 of 57
- Hematology 413
- Oncology 938
- Pathology and Forensic Medicine 387
- Public Health, Environmental and Occupational Health 572
- Immunology 364
Countries citing papers authored by Julia Stieglmaier
This map shows the geographic impact of Julia Stieglmaier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julia Stieglmaier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julia Stieglmaier more than expected).
Fields of papers citing papers by Julia Stieglmaier
This network shows the impact of papers produced by Julia Stieglmaier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julia Stieglmaier. The network helps show where Julia Stieglmaier may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Julia Stieglmaier, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 1 | |
| 3 | 2023 | 1 | |
| 4 | 2023 | 8 | |
| 5 | 2022 | 30 | |
| 6 | 2022 | 7 | |
| 7 | 2021 | 3 | |
| 8 | 2020 | 32 | |
| 9 | 2019 | 41 | |
| 10 | Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemiabreakdown → | 2018 | 516 |
| 11 | 2016 | 142 | |
| 12 | Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphomabreakdown → | 2016 | 280 |
| 13 | 2015 | 53 | |
| 14 | 2014 | 43 | |
| 15 | 2014 | 21 | |
| 16 | 2008 | 62 | |
| 17 | 2008 | 41 | |
| 18 | 2007 | 23 | |
| 19 | 2007 | 53 | |
| 20 | 2006 | 20 |
About Julia Stieglmaier
Julia Stieglmaier is a scholar working on Oncology, Hematology and Radiology, Nuclear Medicine and Imaging, having authored 24 papers that have together received 1.4k indexed citations. Recurring topics across this work include CAR-T cell therapy research (17 papers), Monoclonal and Polyclonal Antibodies Research (8 papers), Cancer Immunotherapy and Biomarkers (6 papers), Acute Lymphoblastic Leukemia research (5 papers), Immunotherapy and Immune Responses (5 papers), Prostate Cancer Treatment and Research (5 papers), Lymphoma Diagnosis and Treatment (5 papers) and Chronic Myeloid Leukemia Treatments (4 papers). The work is most often cited by research in Hematology (413 citations), Oncology (938 citations) and Pathology and Forensic Medicine (387 citations). Julia Stieglmaier has collaborated with scholars based in Germany, United States and Japan. Frequent co-authors include Dirk Nagorsen, Ralf C. Bargou, Jonathan Benjamin, Nicola Gökbuget, Hervé Dombret, Monika Brüggemann, Gerhard Zugmaier, Carlos Graux, Hendrik Wessels and Christoph Faul. Their work appears in journals such as Journal of Clinical Oncology, Blood and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.